Animol Discovery is a biopharmaceutical company focused on identifying and developing next- generation antiparasitics and therapeutics.
Animol Discovery has raised $12.0M in total funding. The most recent round was Series C. The last funding was announced in October 2025.
Animol Discovery's investors include Novalis LifeSciences, Anterra Capital, Finistere Ventures, Endeavor8.
Animol Discovery is headquartered in Boston, United States.
Animol Discovery is a biopharmaceutical company focused on identifying and developing next- generation antiparasitics and therapeutics.
Animol Discovery is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Animol Discovery — Funding & Investors." VCBacked, October 17, 2025, https://www.vcbacked.co/company/animol-discovery. Accessed October 4, 2026.
VCBacked. (2025). Animol Discovery — Funding & Investors. Retrieved October 4, 2026, from https://www.vcbacked.co/company/animol-discovery
{{cite web |title=Animol Discovery — Funding & Investors |url=https://www.vcbacked.co/company/animol-discovery |website=VCBacked |access-date=October 4, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated